TG Therapeutics Overview

  • Founded
  • 2003
Founded
  • Status
  • Public
  • Employees
  • 272
Employees
  • Stock Symbol
  • TGTX
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $33.95
  • (As of Thursday Closing)

TG Therapeutics General Information

Description

TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 2 Gansevoort Street
  • 9th Floor
  • New York, NY 10014
  • United States
+1 (877) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

TG Therapeutics Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$33.95 $32.80 $21.06 - $56.74 $4.68B 143M 1.53M -$2.72

TG Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Jun-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 5,005,719 7,005,131 1,072,167 242,228
Revenue 2,414 152 152 152
EBITDA (337,864) (272,894) (167,484) (172,517)
Net Income (344,506) (279,381) (172,871) (173,482)
Total Assets 481,400 625,642 163,014 83,616
Total Debt 34,844 41,976 40,804 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

TG Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore TG Therapeutics‘s full profile, request access.

Request a free trial

TG Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization
Biotechnology
New York, NY
272 As of 2020
0000
00000000 0000

00 00000

r incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ul
0000000000000
Durham, NC
000 As of 0000
00000
000000 - 000 00000

00000

d exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in rep
0000000000000
Thousand Oaks, CA
00000 As of 0000
00.000
000000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

TG Therapeutics Competitors (5)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
G1 Therapeutics Formerly VC-backed Durham, NC 000 00000 000000 - 000 00000
00000 Formerly PE-Backed Thousand Oaks, CA 00000 00.000 000000000000 00.000
000 000000000000 Venture Capital-Backed Barcelona, Spain 00 0000 00000000000 0000
00000000 Venture Capital-Backed New York, NY 00 0000 00000000000 0000
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000000 00.000
You’re viewing 5 of 5 competitors. Get the full list »

TG Therapeutics Patents

TG Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20190247399-A1 Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers Pending 09-Sep-2016 0000000000
CA-3035976-A1 Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers Pending 09-Sep-2016 0000000000
JP-2019526595-A Combination of anti-cd20 antibody, pi3 kinase-delta inhibitor and anti-pd-1 antibody or anti-pd-l1 antibody for treating blood cancer Pending 09-Sep-2016 0000000000
AU-2017322501-A1 Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers Pending 09-Sep-2016 0000000000
EP-3509634-A1 Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers Pending 09-Sep-2016 A61K31/519

TG Therapeutics Executive Team (4)

Name Title Board Seat Contact Info
Michael Weiss JD Chairman, President & Chief Executive Officer
Sean Power Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Peter Sportelli Chief Operating Officer
Owen O'Connor Ph.D Chief Scientific Officer
To view TG Therapeutics’s complete executive team members history, request access »

TG Therapeutics Board Members (3)

Name Representing Role Since
0000000 00000000 TG Therapeutics Board Member 000 0000
0000000 00000 00 TG Therapeutics Chairman, President & Chief Executive Officer 000 0000
00000 000000 TG Therapeutics Board Member 000 0000
To view TG Therapeutics’s complete board members history, request access »

TG Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TG Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 00000000 12-Mar-2010 000000000000000000 Pharmaceuticals
To view TG Therapeutics’s complete acquisitions history, request access »